SCOTTSDALE, ARIZONA – March 3, 2010
Mary Robbins was a member of Alcor Life Extension Foundation since 2006. Ms. Robbins left her remains to Alcor in a written directive pursuant to the Colorado Disposition of Last Remains Act. A dispute arose between the Robbins family and Alcor over whether or not Ms. Robbins cancelled her written wishes concerning her remains two days before her legal death in Colorado Springs on February 9, 2010.
On March 1, 2010, a Colorado Probate Court ruled that Ms. Robbins did not revoke her written wishes concerning her remains by signing a “change of beneficiary” document in connection with an insurance annuity. The court further ordered that Alcor shall have custody of the remains of Ms. Robbins.
Today, Alcor and the Robbins family reached an amicable settlement in which Alcor will be allowed to transport immediately the frozen remains of Ms. Robbins to Arizona to complete the process of cryopreservation. In exchange, Alcor agreed to release all potential claims to an insurance annuity in which Alcor had been the previously named beneficiary.
Jennifer Chapman, Executive Director of Alcor stated: “We are glad we were able to fulfill the wishes of our long-standing member.”
Colorado counsel for Alcor, Eric Bentley, said, “Even though Ms. Robbins long intended that the annuity go to Alcor in connection with her cryonics arrangements, Alcor decided to release any claims on the funds in the interests of seeing her wishes completed without further delay. Alcor is hopeful this compromise helps the Robbins family find peace and closure.”
Mr. Bentley went on to say, “This case was never about money. Alcor simply wanted to carry out the written desires of Ms. Robbins. Alcor is pleased the matter could be resolved quickly and in the best interests of everyone involved.”
About the Alcor Life Extension Foundation
Alcor Life Extension Foundation is a not-for-profit research organization founded in 1972. Alcor is the world leader in cryonics, and cryonics technology. Cryonics is the science of using ultra-cold temperatures to cryopreserve humans. The intent is that advanced scientific procedures may one day be able to revive cryopreserved humans and restore them to good health. Alcor performed its first human cryopreservation in 1976, and has engaged in long-term care of cryopreserved members in its state-of-the-art facility since then.
Among the scientific achievements of Alcor is the use of advanced cryoprotectant formulas capable of vitrification. Vitrification enables cryopreservation to take place without the damage that occurs in freezing tissue. Alcor has published papers in scientific journals documenting the quality of tissue preservation possible with its procedures, and the effects of clinical death on the brain. Alcor also sponsors research in the field of nanomedicine, a technology that may someday be used to revive cryopreserved patients.
Alcor’s Board of Directors consists of successful and well-regarded scientists, physicians, attorneys and other professionals. Alcor also has a group of scientific advisors, who are leaders in the fields of medical research, nanotechnology, and computer science.
Alcor has more than 900 members and 90 cryopreserved patients. The public is welcome to attend regularly scheduled tours of the Alcor facility in Scottsdale, Arizona. For more information about Alcor and cryonics, visit www.alcor.org.